Call Us Contact Us
+44 1494 818 000     Online Enquiry
Lines open
Monday to Thursday
08:30 to 18:00
Friday
08:30 to 17:30
Pharmaceutical | Medical Devices | Scientific | Consumer Healthcare | Dental | Animal Health | FMCG | Executive
         
Latest Jobs

South London, Croydon, Bromley
10 May 2013 16:26



Redhill, Horsham, Crawley, East Grinstead, Brighto
22 May 2013 14:08



South London, Croydon, Bromley
10 May 2013 10:46



Fife, Tayside, Grampian and Highlands.
10 May 2013 10:46



Cumbria, Northumberland, Newcastle, Gateshead, Sun
15 May 2013 16:35



Head Office
20 May 2013 16:00



Co. Durham, Teesside & Sutherland
14 May 2013 17:54



Surrey
17 May 2013 17:27



South West & Central South Coast
10 May 2013 10:39



Norfolk
10 May 2013 10:38



Edinburgh, Lothian/Borders
17 May 2013 17:39



Chertsey, Surrey
20 May 2013 15:59



South of the UK
13 May 2013 09:35



South West and South East
10 May 2013 10:38


Exclusive vacancies may not be shown here, please contact Alex on +44 1494 818021 or alex@zenopa.com for more information.
Have you registered?
Once you register you can see additional job details, save jobs, track your applications and manage e-lert preferences.

Register now
Alex Reynolds
Account Manager
alex@zenopa.com
+44 1494 818021

Testimonials
I just wanted to take this opportunity to thank you for all your support throughout my interview process with the client.
Annie, 2012

Astellas appoints new market access director

15 August 2012 11:25 in Pharmaceutical Company Restructures


Astellas has named Dr Susan Wood as its new European senior director for market access.

Dr Wood, the former senior brand director of Astellas Pharma Europe's pain management franchise, has been tasked with driving the company's market access activities, while reporting directly to marketing vice-president Kay Drake.

Originally appointed by the company in 2008, Dr Wood has more than 13 years of pharmaceutical marketing experience and led the successful launch of the company's peripheral neuropathic pain therapy Qutenza over the last three years.

This launch demonstrated her abilities as a leader, while also highlighting the value of integrating market access expertise at an early stage of strategic planning.

Ken Jones, president and chief executive officer at Astellas Pharma Europe, said Dr Wood's work will "focus on developing evidence-based models from the early stages of research and development until the mature stages of the product lifecycle".

Last month, the company commenced a new clinical trial of Qutenza, comparing its efficacy and tolerability to pregabalin.ADNFCR-8000103-ID-801429134-ADNFCR

Other news stories from 15/08/2012

Related news

Read more in the Zenopa News Archive

How this news is generated

Story collated for Zenopa by the Adfero News Agency



   
© Copyright 2013 Zenopa Ltd